Skip to content

Ferrous Sulfate Versus Iron Amino Acid Chelate

EFICACIA DEL HIERRO AMINOQUELADO COMPARADO CON EL SULFATO FERROSO COMO COMPLEMENTO ALIMENTARIO EN PREESCOLARES CON DEFICIENCIA DE HIERRO.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01412723
Enrollment
64
Registered
2011-08-09
Start date
2011-10-31
Completion date
2012-04-30
Last updated
2012-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency

Keywords

Iron Deficiency, Child, Preschool, Dietary Iron, Ferrous sulfate, Bis-glycino iron II

Brief summary

Iron deficiency and depleted levels of iron are the most prevalent nutritional deficiency and the leading cause of anemia in the world; this can occur at any age, but preschool children are at particular risk of developing it. This condition may cause serious repercussions for life, being a public health threat of considerable importance worldwide. Food fortification is considered the most effective solution to counter this situation, because it can help more people than other solutions. It is going to carry out a community trial to compare the efficacy of ferrous sulfate with respect to iron amino acid chelate as a dietary supplement in preschool children of Medellin with depleted levels of iron; in terms of increasing ferritin levels in blood and maintain hemoglobin levels. It is hypothesized that at the end of the study the effect of milk fortified with iron amino acid chelate won't be less than the effect of fortified with ferrous sulfate. It is hoped that the results may contribute, albeit indirectly, to improve the health status of children with depleted levels of iron whom consume iron-fortified products.

Interventions

OTHERFerrous sulfate as dietary supplementation

Ferrous sulfate as dietary supplementation

OTHERIron amino acid chelated as dietary supplementation

Iron amino acid chelated as dietary supplementation

Sponsors

Nutreva S.A.S.
CollaboratorUNKNOWN
Foundation Child Care - FAN
CollaboratorOTHER
CES University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Years to 5 Years
Healthy volunteers
No

Inclusion criteria

Children who * Belong to institute FAN in Medellín * Attend full time to institute FAN (eight hours) * Have 2 to 5 years inclusive * Submit depleted levels of iron (ferritin level equal to or less than 24 mg/L)

Exclusion criteria

Children who * Submit anemia (hemoglobin level equal to or less than 11 g/dL) * Have not stool analysis before intervention

Design outcomes

Primary

MeasureTime frameDescription
FerritinUp to 8 weeksThe Ferritin level in blood will be measured at the beginning of the study as one of the most important inclusion criteria. This also will be the base line of the study. After that randomization will be carried out and after two months (time frame which ferrous sulfate or iron aminoacid chelate would increase ferritin level in blood) ferritin level will be measured again as the primary outcome measure.

Secondary

MeasureTime frameDescription
HemoglobinUp to 8 weeksThe Hemoglobin level in blood will be measured at the beginning of the study as one of the most important exclusion criteria. After that randomization will be carried out and after two months (time frame which ferrous sulfate or iron aminoacid chelate would increase ferritin level in blood) hemoglobin level will be measured again as one of secundary outcome measure. The hypothesis is that the hemoglobin level won't decrease
InfectionDaily. During 2 months of interventionDaily written report of the caregiver during the intervention
Adverse reactionDaily. During 2 months of interventionThe caregiver recorded daily if the child had an adverse reaction such as abdominal pain, nausea, vomiting, constipation, diarrhea, darkening of feces, and disgust for food.

Countries

Colombia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026